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Objectives. The present study was designed to assess whether a
diuretic- or an angiotensin-converting enzyme inhibitor–based
treatment can reduce arterial wall hypertrophy of a distal mus-
cular medium-sized artery—the radial artery—and the stiffness of
a proximal large elastic artery—the common carotid artery.
Background. Large-artery wall thickness and stiffness are
increased during sustained essential hypertension and contribute
to the increased risk of complications. Whether antihypertensive
treatment can normalize the wall hypertrophy of conducting
arteries has not yet been determined.
Methods. Seventy-seven elderly hypertensive patients were ran-
domized to receive 9 months of double-blind treatment with
perindopril (2 to 8 mg/day) or the diuretic combination of
hydrochlorothiazide (12.5 to 50 mg/day) plus amiloride (1.25 to
5 mg/day) after a 1-month placebo washout period. If systolic
blood pressure remained at >160 mm Hg after 5 months,
chlorthalidone or atenolol was added, respectively. Arterial vari-
ables, including radial artery mass and common carotid artery
compliance, were calculated from noninvasive measurements of
internal diameter and wall thickness with the use of high resolu-
tion echo-tracking systems at baseline and after 5 and 9 months.
Results. During treatment, blood pressure and arterial vari-
ables changed to the same extent in both groups. After a 9-month
treatment, systolic, diastolic and pulse pressures and radial artery
wall thickness, mass and thickness/radius ratio decreased signif-
icantly (p < 0.01), whereas carotid compliance increased (p <
0.001). The decrease in radial artery thickness/radius ratio after a
9-month treatment was significantly related to the reduction in
pulse pressure (p < 0.01), whereas the improvement in carotid
compliance was related to the reduction in mean arterial pressure
(p < 0.01). In healthy subjects and untreated hypertensive
patients, radial artery diameter, wall thickness and thickness/
radius ratio and carotid artery compliance did not change signif-
icantly during a 9-month observation period.
Conclusions. These results indicate that in elderly hypertensive
patients, both angiotensin-converting enzyme inhibitor– and di-
uretic combination–based treatments can reduce radial artery
wall hypertrophy and improve carotid artery compliance.
(J Am Coll Cardiol 1998;31:1064–73)
©1998 by the American College of Cardiology
During sustained essential hypertension, structural changes in
the cardiovascular system are associated with an independent
increased risk of cardiovascular disease and death. Most
evidence concerns left ventricular hypertrophy (1,2). Increased
arterial wall thickness, which is influenced not only by elevated
mean blood pressure but also by high pulse pressure (3–6),
contributes to the normalization of circumferential wall stress
in patients with hypertension (7,8), parallels the development
of left ventricular hypertrophy (9) and could potentiate the
development of atherosclerosis at some arterial sites, like the
carotid artery (6,10).
Experimental studies in rats have shown that the reversibil-
ity of structural vascular changes during antihypertension
treatment may be obtained in the larger (11–13) as well as the
smaller (14,15) arteries. Although long-term antihypertension
treatment may correct in part the structural abnormalities
present in the subcutaneous arteries of patients with mild
hypertension (16), there is little evidence for extrapolation to
large arteries in humans. Investigations of large arteries have
shown that the reverse may be very difficult to obtain (17).
Because angiotensin-converting enzyme (ACE) inhibitors have
been shown to induce a significant regression in large artery
wall hypertrophy in animals with hypertension (11–13), perin-
dopril, which was demonstrated to have efficacy in animals
(11), was used in the present study and compared with the use
of a combination of a thiazide diuretic plus amiloride. The
thiazide diuretic hydrochlorothiazide (HCTZ) was selected be-
cause it is commonly used in the management of hypertension
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in the elderly and has been used in intervention trials in the
elderly with (18) and without (19,20) isolated systolic hyper-
tension. In addition, ACE inhibitors and thiazide diuretics
have demonstrated efficacy in decreasing left ventricular mass
(21). Because pulse pressure is an important factor of vascular
hypertrophy (3–6) and large-artery distensibility is one of the
main determinants of pulse pressure, in addition to wave
reflections (22–24), we also investigated the effects of antihy-
pertension treatment on the elastic properties of the common
carotid artery (CCA).
The objective of the present study was to determine
whether drug treatment of hypertension, with either a diuretic
or an ACE inhibitor is able to obtain the reverse of functional
and structural arterial changes in elderly patients with hyper-
tension. Two arterial sites were considered: a proximal, pre-
dominantly elastic, large artery, the CCA, for assessment of the
effects of long-term antihypertension treatment on arterial
distensibility, and a distal, medium-sized, predominantly mus-
cular artery, the radial artery, for evaluation of the regression
of arterial wall hypertrophy during treatment.
Methods
Patients. The study was conducted in two centers, one in
France and one in Italy, and was named PERICLES (PERIn-
dopril and hydrochlorothiazide 1 amiloride for the Control at
Long term of wall thickness in ESsential hypertension). One
hundred three patients with hypertension between 60 and 80
years old with or without isolated systolic hypertension (systol-
ic blood pressure [SBP] .160 mm Hg regardless of diastolic
pressure [DBP]) were selected for participation in the study.
The diagnosis of essential hypertension was established by the
absence of clinical evidence of secondary hypertension. Pa-
tients were included in the study if they had normal serum
electrolyte and creatinine levels. Exclusion criteria were con-
gestive heart failure, myocardial infarction or cerebrovascular
accident within the past 3 months, unstable angina pectoris,
overt atherosclerotic lesions, diabetes mellitus treated with
insulin or oral antidiabetic agents or serum creatinine of .200
mmol/liter.
Patients entered a single-blind, placebo-controlled washout
period that lasted 1 week for patients not previously treated
with antihypertensive agents and 4 weeks for patients receiving
antihypertensive agents. Placebo was administered once daily
in the morning. After the placebo washout period, patients
with an SBP between 160 and 230 mm Hg and a DBP of
,120 mm Hg were included in the study. The upper limits of
SBP of 230 mm Hg and DBP of 120 mm Hg were chosen for
safety, like in the STOP-Hypertension trial (19). Blood pres-
sure was recorded as the mean value of three consecutive
measurements obtained with a standard mercury sphygmoma-
nometer after 15 min of rest in the sitting position. Korotkoff
phases 1 and 5 were taken as SBP and DBP, respectively.
Patients were excluded if the fall in SBP was .30 mm Hg
between sitting and standing measurements.
After inclusion, patients were stratified at each center and
randomized to receive a 9-month treatment with either perin-
dopril (2 mg/day) or HCTZ (12.5 mg/day) plus amiloride
(1.25 mg/day) each morning in a double-blind fashion. After 1
month, the dosage was doubled. After the 1-month follow-up
visit, drugs were titrated during follow-up to achieve goal
blood pressure. The goal was a decrease in sitting SBP of
.30 mm Hg in patients with an initial SBP of .200 mm Hg or
a decrease in sitting SBP of .20 mm Hg in patients with initial
SBP between 160 and 200 mm Hg. At 3 months, the dosage
was doubled if patients had not achieved goal blood pressure.
At 5 months, chlorthalidone was added at a dosage of 12.5 mg
once daily for patients randomized to receive perindopril, and
atenolol was added at a dosage of 50 mg once daily for patients
randomized to receive hydrochlorothiazide plus amiloride. At
7 months, these dosages were doubled. Weight, blood pres-
sure, heart rate, clinical acceptability and patient adherence to
therapy were assessed at each visit during the active treatment
period (months 1, 3, 5 and 7). During the follow-up, patients
were withdrawn from the study if they had an SBP of
.230 mm Hg or a DBP of .120 mm Hg (at the maximal dose).
Treatment was discontinued in patients who experienced seri-
ous adverse effects or major intercurrent disease or in the case
of poor patient adherence. Patients were asked about their
adherence to therapy at each visit, and the number of capsules
returned at the end of each treatment period was counted and
compared with the number of days of treatment. Patients
having taken ,70% of their capsules were excluded from study
analysis. Routine laboratory tests were obtained at inclusion,
and arterial measurements were made at inclusion and after 5
and 9 months of active treatment.
Of the 103 patients who were initially eligible, 84 were
randomized to receive treatment. Three patients were ex-
cluded due to orthostatic hypotension, and 16 were excluded
because their SBP was not high enough after the wash-out
period to meet the inclusion criteria. Of the 84 patients
randomized to receive treatment, 77 completed the study.
Among the 7 patients withdrawn before the end of the study,
2 were excluded due to poor compliance with drug treatment,
1 because of a minor side effect (cough), 3 because of severe
intercurrent medical problems (cirrhosis decompensation, in-
termittent leg claudication, pulmonary embolism) and 1 due to
protocol violation (unauthorized treatment). The 7 patients
withdrawn before the end of the study were compared with the
77 patients who completed the study; no significant difference
was observed between the two groups with regard to baseline
biologic characteristics. No serious side effects related to
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CCA 5 common carotid artery
DBP 5 diastolic blood pressure
HCTZ 5 hydrochlorothiazide
RF 5 radiofrequency
SBP 5 systolic blood pressure
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treatments occurred during the study in the remaining 77
patients. Thirty-eight patients were included in the perindopril
group, and 39 were included in the HCTZ-plus-amiloride
group. Thirty-two patients in the perindopril group and 27 in
the HCTZ-plus-amiloride group had previously been treated
with antihypertensive agents. The protocol was approved by
the ethical committee of each participating center. Written
informed consent to participate in the study was obtained from
each subject.
Repeatability study. Thirteen healthy subjects and patients
with hypertension (mean age 6 SD 45 6 7 years) were
included in a long term (9 6 1 months) repeatability study of
carotid and radial artery measurements. The 8 healthy subjects
included in the study had a normal physical examination and
SBP and DBP of ,140 and ,85 mm Hg, respectively. They
were untreated during the follow-up. Five patients with hyper-
tension, who were followed at the Hypertension Clinic of
Broussais Hospital, had essential hypertension and remained
hypertensive despite treatment.
Measurements. The investigation was performed in a con-
trolled environment maintained at 22 6 1°C. Blood pressure
and arterial measurements were made between 2 and 5 h after
the treatment and at the same time of the day for each patient
during the study. Blood pressure measurements were made
with the standard mercury sphygmomanometer and ausculta-
tory method. Blood pressure and arterial measurements were
performed by two senior physicians, in Paris (X.G.) and Milan
(C.G.), who followed the training sessions and were certified.
Radial artery variables. Internal diameter and wall thick-
ness. Radial artery internal diameter and wall thickness were
measured with a high resolution pulsed ultrasound echo-
tracking device (NIUS 02; SMH, Bienne, Switzerland; mar-
keted by Capital Medical Services, Paris, France) described
and validated previously (25–29). Briefly, a 10-MHz probe was
used to acquire backscattered radiofrequency (RF) data from
the radial artery at the wrist. The transducer is placed perpen-
dicular to the arterial axis, in its largest cross-sectional dimen-
sion, with a stereotactic arm, so its focal zone is located in the
center of the artery and the backscattered echoes from both
the anterior and posterior walls can be visualized. To measure
the internal diameter and intima-media wall thickness of the
posterior wall, electronic trackers are positioned on specific
peaks of the RF ultrasound signal, as described previously
(25,28). All data processing was performed with software
developed by Asulab (Neuchatel, Switzerland). The pulse
length of this 10-MHz ultrasound system was 0.1 ms at 6 dB
and corresponded to a practical axial resolution of 0.16 mm for
absolute internal diameter or wall thickness measurements and
0.0025 mm for these parameters during systolic-diastolic
changes.
Mean internal diameter and wall thickness were calculated
by integrating the time course of the systolic-diastolic varia-
tions over $20 consecutive cardiac cycles. At the end of the
study, tracings obtained for the radial artery were cross-
checked by the two physicians (X.G. and C.G.), who were
unaware of treatment, clinical data, date of acquisition and
rank of study visit for the patients. If the quality of a tracing
was found to be nonacceptable for analysis, the tracing was
reanalyzed by the two readers to reach a consensus. With these
criteria, 13 of 231 tracings were rejected, and only patients with
acceptable tracings obtained at the three visits were included in
the statistical analysis. Thus, radial artery variables were
analyzed in 33 patients of the perindopril group and 33
patients of the HCTZ-plus-amiloride group.
Thickness/radius ratio (%) was calculated as follows:
2h/Di, [1]
where h 5 mean wall thickness and Di 5 mean internal
diameter. Mean circumferential wall stress (kPa) was calcu-
lated according to Lame´’s equation as follows:
su 5 MBPz2h/Di, [2]
where MBP 5 mean blood pressure, calculated as DBP 1 1⁄3
(SBP 2 DBP).
Because wall thickness is influenced by instantaneous vari-
ations in blood pressure level, radial artery mass is a more
appropriate variable due to the incompressibility of the arterial
mass (8). Radial artery mass was calculated as follows:
RAM 5 rL~pRe2 2 pRi2!, [3]
where r 5 arterial wall density (r 5 1.06), L 5 length of the
arterial segment and Re and Ri 5 values of mean internal and
external radii, respectively. Radial artery mass was normalized
to the length of the arterial segment and expressed as mg/cm
(length). The calculation of the radial artery mass has been
described and validated previously (7,28).
Long-term repeatability. Long-term repeatability of radial
artery diameter, wall thickness, thickness/radius ratio and
radial artery mass measurements was investigated in a group of
13 healthy subjects and patients with hypertension through
calculation of the absolute difference, variation coefficient and
repeatability coefficient (RC). The repeatability coefficient was
defined by the British Standard Institution (30) according to
the formula RC2 5 S Di
2/N, where RC 5 the repeatability
coefficient, N 5 sample size and Di 5 relative difference within
each pair of measures. This coefficient is the SD of the
estimated difference between two repeated measurements.
The 95% confidence interval of the expected difference was
calculated as 61.96 RC. Repeated measurements are expected
to differ by more than the confidence interval with a probability
of only 5%. This long-term intraobserver repeatability study
compared two determinations obtained by the same observer
at a 9 6 1-month interval.
Carotid artery variables. The CCA measurements were
performed after radial artery measurements, with the patient
in the recumbent position. The measurement site was the right
CCA, 2 cm beneath the carotid bifurcation. Very few patients
(four in the HCTZ-plus-amiloride group and three in the
perindopril group) had atherosclerotic plaques at the site of
the CCA. In these patients, the contralateral carotid artery was
devoid of atherosclerotic plaque and was used for compliance
measurements on the repeat study.
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Internal diameter. The vessel wall properties of the right
CCA were assessed with a pulsed ultrasound echo-tracking
system (Wall-Track System; Neurodata, Maastricht, The Neth-
erlands) developed to measure the wall motion of superficial
large arteries after B-mode echographic localization. This
system has been described in detail (31) and has been used in
clinical studies (32,33). Because of the accurate determination
of the Doppler frequency (phase-locked echo-tracking sys-
tem), a stereotactic device is not necessary to obtain reliable
measurements. Briefly, this system allows the transcutaneous
assessment of arterial wall displacement during successive
cardiac cycles and hence of the time-dependent changes in
arterial wall diameter relative to its initial diameter at the start
of the cardiac cycle. Based on the two-dimensional B-mode
image, an M line perpendicular to the longitudinal and trans-
verse axes of the artery is selected 2 cm below the CCA
bifurcation. The RF signal over four to eight cardiac cycles is
digitized and stored temporarily; the device has large memory
capability. Two sample volumes, selected under cursor control,
are positioned on the anterior and posterior walls, respectively.
The vessel walls are continuously tracked by sample volume
according to phase. Then the displacement of the arterial walls
is obtained by autocorrelation processing of the Doppler signal
originating from the sample volumes. The accuracy of the
system is 30 mm for diastolic diameter measurement and
,1 mm for the pulsatile change in diameter (systolic diameter
minus diastolic diameter).
Distensibility and compliance. Arterial stiffness parameters
were derived from analysis of the pressure-volume relation-
ship. Compliance and volume distensibility were defined as
compliance 5 DV/DP and distensibility 5 DV/(V 3 DP), where
V 5 arterial volume, DV 5 change in volume and DP 5 change
in pressure. It is assumed that the increase in volume of an
arterial segment is almost exclusively caused by an increase in
radius because elongation is negligible in vivo at this site (8,34).
Thus, arterial compliance and distensibility can be estimated
on the basis of the variations in arterial cross-sectional area
(DA) and blood pressure (DP) during systole (31). Cross-
sectional distensibility coefficient is defined as
DC 5 DA/AzDP, [4]
where A 5 diastolic lumen area. Cross-sectional compliance
can be defined as
CC 5 DA/DP. [5]
Carotid pulse pressure was estimated as the difference
between SBP and DBP, as measured with an oscillometric
recorder (Dinamap Model 845; Critikon) at the site of the
brachial artery; the amplification of the pressure wave between
the aortic arch and brachial artery decreases with age and
blood pressure (35,36), leading to similar amplitudes of carotid
and brachial pulse pressures in patients 60 to 70 years old (36).
Measurements were obtained automatically every 3 min. Sev-
eral studies have documented the close correlation between
peak Dinamap SBP and DBP readings and corresponding
central aortic pressures in adults with and without hyperten-
sion (37–39).
Statistical analysis. The primary goal of this study was to
analyze the arterial changes after 9 months of follow-up. All
results are reported according to an efficacy sample analysis.
Data are expressed as mean values 6 SD, unless otherwise
stated. The homogeneity of the randomized groups at baseline
was determined with an unpaired Student t test for continuous
variables and a chi-square test for categorical variables. For
comparison of serial changes in blood pressure and arterial
parameters, repeated-measures analysis of variance (period
and group) was performed to examine treatment differences
and interactions (period 3 group) (40). Because no “center
effect” was significant, the two populations of the study were
analyzed as a whole. The effects of biologically relevant
variables (patient age, weight, baseline blood pressure and
magnitude of SBP and DBP change with treatment and heart
rate at baseline and after treatment) on the study end points
were analyzed with multivariate regression analysis. To deter-
mine whether there were drug-specific effects, the group
(either HCTZ-plus-amiloride or perindopril) was included in
this analysis. Statistical analysis was performed with SAS
software. Statistical significance was assumed for p , 0.05.
Results
Patient characteristics, blood pressure and heart rate.
Patient demographics are shown in Table 1. The 38 and 39
patients randomized to perindopril- and HCTZ-plus-amiloride–
based treatments, respectively, were similar in age, gender
ratio, height, weight, blood pressure before treatment and
blood biochemistry values.
Perindopril- and HCTZ-plus-amiloride–based treatments
produced similar reductions in SBP, DBP and mean and pulse
Table 1. Baseline Characteristics of Patients
Perindopril
(n 5 38)
HCTZ 1 A
(n 5 39)
Clinical variables
Age (yr) 67 6 6 69 6 7
Men/women 12/26 12/27
Height (cm) 160 6 7 162 6 7
Weight (kg) 70 6 11 68 6 12
SBP (mm Hg) 180 6 16 178 6 13
DBP (mm Hg) 99 6 9 95 6 8
Heart rate (beats/min) 84 6 11 78 6 11
Biologic variables
Total cholesterol (mmol/liter) 6.02 6 0.94 6.22 6 1.04
LDL cholesterol (mmol/liter) 4.03 6 0.92 4.14 6 1.01
HDL cholesterol (mmol/liter) 1.45 6 0.37 1.43 6 0.39
Triglycerides (mmol/liter) 1.4 6 0.9 1.3 6 0.5
Fasting glycemia (mmol/liter) 5.8 6 1.2 5.7 6 1.1
Creatinine (mmol/liter) 84 6 19 85 6 23
Data presented are mean value 6 SD or number of patients. A 5 amiloride;
DBP 5 diastolic blood pressure; HCTZ 5 hydrochlorothiazide; HDL 5 high
density lipoprotein; LDL 5 low density lipoprotein; SBP 5 systolic blood
pressure.
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pressures (Table 2). In both groups, the decreases in SBP, DBP
and mean blood pressures were significant by 5 months.
Sixteen patients among the perindopril group required the
addition of chlorthalidone and 10 among the HCTZ-plus-
amiloride group required the addition of atenolol to achieve
the goal blood pressure. After 9 months of treatment, sitting
SBP decreased by 26 mm Hg with perindopril and by
32 mm Hg with HCTZ-plus-amiloride. DBP decreased by
11 mm Hg in both groups. Heart rate remained unchanged
with perindopril and HCTZ-plus-amiloride but was higher in
the perindopril group than in the HCTZ-plus-amiloride group
throughout the study. There was no significant decrease in
heart rate between months 5 and 9 when the 10 patients who
required the addition of atenolol to HCTZ-plus-amiloride
(from 76 6 7 to 73 6 10 beats/min) were compared with the 29
patients who remained under monotherapy (from 73 6 9 to
74 6 9 beats/min). The changes in laboratory values (including
serum potassium level) were not statistically significant.
Radial artery variables. Table 3 shows the radial artery
variables for both treatment groups at baseline and during
follow-up. At baseline, mean values did not differ significantly
between the groups. During antihypertension treatment with
the perindopril- and the HCTZ-plus-amiloride–based regi-
mens, the radial artery exhibited a significant decrease in wall
thickness, mass and thickness/radius ratio (period effect). After
9 months, the wall thickness changes were ;7% (221 mm) and
Table 2. Changes in Sitting Blood Pressure and Heart Rate During Treatment*
Baseline 5 mo 9 mo
p Value (analysis of variance)
Group
Effect
Period
Effect
Group 3 Period
Interaction
SBP (mm Hg)
HCTZ 1 A† 178 6 13 153 6 16 146 6 11 NS , 0.01 NS
Perindopril‡ 180 6 16 159 6 18 154 6 15
DBP (mm Hg)
HCTZ 1 A† 95 6 8 88 6 7 84 6 7 NS , 0.01 NS
Perindopril‡ 99 6 9 89 6 8 88 6 7
Mean BP (mm Hg)
HCTZ 1 A† 123 6 8 110 6 10 105 6 9 NS , 0.01 NS
Perindopril‡ 126 6 10 112 6 9 110 6 10
Pulse pressure (mm Hg)
HCTZ 1 A† 83 6 11 65 6 10 62 6 11 NS , 0.01 NS
Perindopril‡ 81 6 13 70 6 11 66 6 12
Heart rate (beats/min)
HCTZ 1 A† 73 6 9 73 6 7 73 6 9 , 0.05 NS NS
Perindopril‡ 79 6 11 75 6 7 75 6 7
*Sitting blood pressure (BP) was measured with a sphygmomanometer. †n 5 39. ‡n 5 38. Data presented are mean
value 6 SD. Other abbreviations as in Table 1.
Table 3. Changes in Radial Artery Variables During Treatment
Baseline 5 mo 9 mo
p Value (analysis of variance)
Group
Effect
Period
Effect
Group 3 Period
Interaction
Internal diameter (mm)
HCTZ 1 A* 2.35 6 0.35 2.37 6 0.36 2.38 6 0.41 NS NS NS
Perindopril† 2.46 6 0.37 2.46 6 0.34 2.49 6 0.42
Wall thickness (mm)
HCTZ 1 A* 298 6 63 273 6 63 264 6 57 NS , 0.01 NS
Perindopril† 282 6 64 274 6 66 261 6 65
Radial artery mass (mg/cm)
HCTZ 1 A* 26.9 6 9.1 24.5 6 8.3 23.8 6 8.2 NS , 0.01 NS
Perindopril† 26.3 6 10.0 25.4 6 9.0 24.5 6 9.3
Thickness/radius (%)
HCTZ 1 A* 0.25 6 0.04 0.23 6 0.05 0.23 6 0.05 NS , 0.01 NS
Perindopril† 0.23 6 0.05 0.22 6 0.05 0.21 6 0.04
Circumferential wall stress (kPa)
HCTZ 1 A* 64 6 13 61 6 14 62 6 14 NS NS NS
Perindopril† 70 6 15 64 6 13 67 6 12
*n 5 33. †n 5 33. Data presented are mean value 6 SD. HCTZ 1 A 5 hydrochlorothiazide plus amiloride.
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211% (234 mm) in the perindopril and HCTZ-plus-amiloride
groups, respectively. The corresponding changes in radial
artery thickness/radius ratio were ;29% (20.02) and ;28%
(20.02), and changes in radial artery mass were ;27% (21.8
mg/cm) and 211% (23.1 mg/cm). No significant period 3
group interaction was observed, indicating radial artery wall
thickness, mass and thickness/radius ratio decreased to the
same extent in both groups.
The effects of biologically relevant variables (patient age,
weight, baseline blood pressure and magnitude of SBP and
DBP change with treatment and heart rate at baseline and
during treatment) on the radial artery end points were ana-
lyzed using a multivariate regression analysis. To determine
whether there were drug-specific effects, the group (either
HCTZ-plus-amiloride or perindopril) was included in the
analysis. There was a significant relation between the final
(month 9) wall thickness and the percent decrease in pulse
pressure between months 9 and 0 (p 5 0.013) independent of
gender (p , 0.001). Similarly, a significant relation was ob-
served between the final (month 9) thickness/radius ratio and
the percent (p 5 0.001) or absolute (p 5 0.014) decrease in
pulse pressure between months 9 and 0. Group treatment, age,
baseline SBP and DBP, magnitude of SBP and DBP change
with treatment and heart rate at baseline and during treatment
were not significantly related to final radial artery wall thick-
ness or thickness/radius ratio when included in the multivariate
analysis. These results indicate that the alterations in the radial
artery end points (month 9) are simply dependent on efficacy
of pulse pressure lowering and suggest there were no drug-
specific effects. Among the population as a whole, the decrease
in thickness/radius ratio after 9 months of treatment was
significantly related to the reduction in pulse pressure (r 5
0.411, p , 0.01) independent of age (r 5 0.320, p , 0.01) and
changes in mean blood pressure.
In both groups, internal diameter and circumferential wall
stress remained unchanged throughout the study.
Carotid artery variables. Table 4 shows the mean values of
carotid artery variables at baseline and during follow-up with
each treatment. No significant change in internal diameter or
absolute or relative pulsatile changes in diameter were ob-
served for each group. Absolute and relative pulsatile changes
in diameter were significantly lower in the perindopril group
than in the HCTZ-plus-amiloride group (group effect).
During antihypertension treatment with the perindopril-
and HCTZ-plus-amiloride–based regimens, a significant in-
crease in CCA distensibility and compliance was observed
(period effect). After 9 months, the distensibility changes were
;133% (12.2 kPa21z1023) and ;138% (3.0 kPa21z1023) in
the perindopril and HCTZ-plus-amiloride groups, respectively.
The corresponding CCA compliance changes were ;128%
(10.9 m2zkPa21z1027) and ;129% (11.1 m2zkPa21z1027). No
significant period 3 group interaction was observed, indicating
CCA distensibility and compliance were improved to the same
extent by treatment in each group. Compliance and distensi-
bility remained lower in the perindopril group than in the
HCTZ-plus-amiloride group throughout the study, including
baseline values.
Among the cohort as a whole, the increases in CCA
distensibility and compliance with treatment were significantly
related to the reduction in mean arterial pressure (r 5 20.397,
p , 0.01; and r 5 20.281, p , 0.05, respectively).
No significant difference in baseline characteristics (includ-
ing radial and carotid artery variables) or responses to treat-
ment was observed between the 51 patients who remained
under monotherapy and the 26 patients who required bi-
therapy.
Repeatability study in control subjects and patients. Table
5 summarizes the long term intraobserver repeatability of
Table 4. Changes in Common Carotid Artery Variables During Treatment
Baseline 5 mo 9 mo
p Value (analysis of variance)
Group
Effect
Period
Effect
Group 3 Period
Interaction
Internal diameter (mm)
HCTZ 1 A* 7.81 6 0.79 7.58 6 0.88 7.60 6 0.88 NS NS NS
Perindopril† 7.93 6 0.90 7.78 6 0.76 7.78 6 0.80
Ds 2 Dd (mm)
HCTZ 1 A* 354 6 146 316 6 112 351 6 128 , 0.05 NS NS
Perindopril† 294 6 92 283 6 77 304 6 88
(Ds 2 Dd)/Dd (%)
HCTZ 1 A* 4.5 6 1.7 4.2 6 1.2 4.6 6 1.5 , 0.05 NS NS
Perindopril† 3.8 6 1.2 3.7 6 1.1 4.0 6 1.2
CS compliance (m2zkPa21z1027)
HCTZ 1 A* 3.8 6 1.9 4.4 6 2.1 4.9 6 1.8 , 0.05 , 0.01 NS
Perindopril† 3.2 6 1.4 3.6 6 1.2 4.1 6 1.4
CS distensibility (kPa21z1023)
HCTZ 1 A* 7.7 6 3.3 9.5 6 3.2 10.7 6 3.4 , 0.05 , 0.01 NS
Perindopril† 6.6 6 2.8 7.9 6 2.7 8.8 6 3.2
*n 5 39. †n 5 38. Data presented are mean value 6 SD. HCTZ 1 A 5 hydrochlorothiazide 1 amiloride; CS 5
cross-sectional; Ds 2 Dd 5 absolute pulsatile change in diameter; (Ds 2 Dd)/Dd 5 relative pulsatile change in diameter.
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radial and carotid artery variables in 13 healthy subjects and
patients with hypertension. The repeatability coefficients of the
various variables were small compared with the mean baseline
values. In the 8 healthy subjects, radial artery diameter, wall
thickness, thickness/radius ratio and mass remained un-
changed after 9 months (2.26 6 0.28 vs. 2.20 6 0.21 mm, 196 6
22 vs. 196 6 23 mm, 0.17 6 0.02 vs. 0.18 6 0.02 and 16 6 3 vs.
16 6 3 mg/cm, respectively). In the 5 patients with hyperten-
sion, radial artery diameter, wall thickness, thickness/radius
ratio and mass remained unchanged after 9 months (2.47 6
0.40 vs. 2.62 6 0.30 mm, 287 6 26 vs. 281 6 19 mm, 0.24 6 0.05
vs. 0.22 6 0.01 and 26 6 5 vs. 27 6 5 mg/cm, respectively).
In the eight healthy subjects, carotid artery diameter, stroke
change in diameter and compliance did not change signifi-
cantly after 9 months (6.22 6 1.03 vs. 6.63 6 1.11 mm, 458 6
164 vs. 385 6 137 mm and 6.2 6 2.2 vs. 5.9 6 2.2
m2zkPa21z1027, respectively). In the five patients with hyper-
tension, carotid artery diameter, absolute pulsatile change in
diameter and compliance remained unchanged after 9 months
(6.68 6 0.37 vs. 6.40 6 0.12 mm, 343 6 140 vs. 340 6 111 mm
and 3.8 6 2.3 vs. 3.9 6 1.9 m2zkPa21z1027, respectively).
Discussion
To our knowledge, the present study is the first controlled,
blinded study of whether antihypertension treatment reduces
intima-media thickness at the site of a medium-sized artery.
The results indicate that in elderly patients with hypertension,
the intima-media thickness of a peripheral muscular artery, the
radial artery and the stiffness of a proximal elastic artery, the
CCA, were reduced after 9 months of a perindopril- or
HCTZ-plus-amiloride–based treatment. The reduction in the
radial artery wall/lumen ratio was directly related to the
decrease in pulse pressure, whereas the decrease in carotid
stiffness was directly related to the decrease in mean blood
pressure.
Regression of radial artery wall hypertrophy. During sus-
tained essential hypertension, large and medium-sized artery
wall hypertrophy may represent target organ damage, like left
ventricular hypertrophy or impaired renal function (1,6,17,
23,41). The increase in arterial wall thickness contributes to the
normalization of circumferential wall stress (7,8), parallels the
development of left ventricular hypertrophy (9) in patients
with hypertension and could potentiate the development of
atherosclerosis at some arterial sites, like the carotid artery
(6,10).
One of the main results of the present study is that in
elderly persons with essential hypertension, both ACE inhibi-
tor– and diuretic-based treatments reduced radial artery
intima-media thickness. This result is consistent with studies in
animals with hypertension that have shown that the reversibil-
ity of structural vascular changes during antihypertension
treatment can be obtained in the large arteries (11–13).
Although in humans long-term antihypertension treatment has
been reported to correct in part the structural abnormalities
present in the small arteries with mild hypertension (16), to the
best for our knowledge no study reported such findings at the
site of medium-sized arteries. Whether one pharmacologic
class of antihypertensive agents causes a greater normalization
of the structure of small arteries (16) and left ventricle (21, 42,
43) than other classes for an equal antihypertension effect in
humans remains a matter of debate. In the elderly patients
with hypertension in the present study, the ACE inhibitor
perindopril decreased radial artery intima-media thickness, as
did the combination of HCTZ-plus-amiloride. Antihyperten-
sion treatments likely reduced wall thickness through a non-
specific effect (i.e., the lowering of distending blood pressure)
because circumferential wall stress did not change with treat-
ment and the reduction in thickness/radius ratio was signifi-
cantly related to the decrease in SBP or pulse pressure among
patients as a whole.
Although the objective of the present study was not to
compare the radial artery intima-media thickness of untreated
persons with hypertension with that of persons without hyper-
tension, it is noteworthy that the radial artery wall of elderly
patients with untreated hypertension was thicker than that of
the younger subjects without hypertension who were included
in the repeatability study. In addition, radial artery wall
thickness of persons with and without hypertension, as ob-
served in the present study, were similar to those reported for
untreated middle-aged persons with and without hypertension,
respectively (7). Thus, the decrease in radial artery intima-
media thickness that we observed in the patients with hyper-
tension in the present study can be considered a regression of
arterial wall hypertrophy.
Radial artery site for measurement of intima-media thick-
ness. The radial artery site was selected for assessment of the
reduction of intima-media thickness for various reasons. First,
ultrasound examination is easy to perform because of its
superficial rectilinear course and the absence of lateral move-
Table 5. Long-Term Intraobserver Repeatability of Radial and
Carotid Artery Variables Measurements in 13 Subjects and Patients
With Hypertension
Baseline
Value
Absolute
Difference*
Variation
Coefficient†
Repeatability
Coefficient‡
Radial artery
Diameter (mm) 2.36 6 0.34 0.13 6 0.09 5.6% 0.16
Wall thickness
(mm)
229 6 48 13 6 9 5.6% 15
Thickness/radius 0.19 6 0.03 0.02 6 0.02 9.2% 0.03
Radial artery mass
(mg/cm)§
20.2 6 6.9 1.0 6 0.7 5.4% 1.4
Carotid artery
Diameter (mm) 6.42 6 0.90 0.48 6 0.35 7.8% 0.36
Ds 2 Dd (mm) 381 6 117 46 6 35 13.9% 60
Compliance
(m2zkPa21z1027)
5.2 6 2.2 0.9 6 0.7 19.2% 0.15
*Absolute change after 9 6 1 months. †Absolute difference/Mean 3 100.
‡(SDi
2/n)1/2. §Units of radial artery mass are mg/cm length of arterial segment
(see text). Data presented are mean value 6 SD. Ds 2 Dd 5 absolute pulsatile
change in diameter.
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ment at the wrist (7,26,27). Second, in essential hypertension,
structural changes in the large artery wall involve an increased
amount of vascular smooth muscle, which is more susceptible
to detection in a muscular than in an elastic artery. Because the
radial artery is a muscular artery devoid of atherosclerotic
lesions, even in patients with severe coronary disease (28),
intima-media thickening should reflect morphological changes
independent of atherosclerotic lesions. This is of particular
relevance for any pathophysiologic study carried out in indi-
viduals with essential hypertension, because it is not possible to
noninvasively differentiate the hypertension-induced wall
thickening from atherosclerotic lesions at various arterial sites
such as the carotid artery (9,44). Third, we had the unique
opportunity of comparing in vivo and in vitro measurements in
patients who were scheduled for coronary artery bypass graft
surgery using the radial artery and to use in vitro ultrasonic and
histologic measurements to validate in vivo measurements
made with the high resolution echo-tracking system NIUS 02
(7).
Study limitations. Because the present study was not a
placebo-controlled study, for obvious ethical reasons, and
because no drug proved to be more efficacious than the other,
one may question whether antihypertension treatment truly
reduced radial artery intima-media thickness. However, sev-
eral findings strongly suggest that a time effect is very unlikely
and that true regression of radial artery wall hypertrophy
occurred in these patients with hypertension. A major argu-
ment is that in the healthy subjects and patients with hyper-
tension included in the repeatability study, wall thickness,
thickness/radius and ratio and radial artery mass remained
unchanged with time. Second, the repeatability coefficients of
radial artery parameters were low compared with their respec-
tive baseline values (Table 5). Third, tracings were read by two
physicians who were blinded to treatment, clinical data and
study visit; thus, a sequence bias could not have occurred.
Fourth, a multiple regression analysis showed that the final
(month 9) thickness/radius ratio was related not only to the
baseline value but also to the in-treatment reduction in pulse
pressure. Fifth, the reduction in radial artery mass observed
with treatment in the present study is close, in relative value, to
those obtained in various long term studies showing a reduc-
tion in left ventricular mass (42,43,45). Therefore, our conclu-
sion that the reduction in wall thickness represents a true
regression of radial artery wall hypertrophy seems well
founded.
The second important result of this study is the absence of
significant period 3 group interaction for the radial artery
parameters. We can conclude that radial artery intima-media
thickness, mass and thickness/radius ratio decreased to the
same extent in the perindopril- and diuretic-based treatment
groups. Could this result be a false negative? A power calcu-
lation (alpha 5 0.05) estimates that with the given number of
subjects and the given SDs, we had an 84% likelihood of
detecting a difference in intima-media thickness between
groups at 9 months (regardless of whether patients remained
on monotherapy) of .29 mm, a value that represents a 10%
reduction in baseline intima-media thickness. Any difference
smaller than that may be considered of little relevance in view
of the intersubject variability observed in the present study and
previous studies (7,28).
Improvement of carotid compliance under treatment. In-
creased arterial stiffness in hypertension contributes to a
further rise in SBP and pulse pressure at any given value of
mean arterial pressure (22,23). The increase in pulse pressure
has been shown to be independently associated with an
increase in coronary and cardiac disease and death (46–48).
Animal (3,4) and clinical (5) studies have shown that the
increased load due to pulse pressure represented for small
arteries a higher determinant of structural abnormalities than
mean arterial pressure. In the present study, the significant
relationship between the reduction in pulse pressure and the
decrease in radial artery thickness/radius ratio suggests that for
medium-sized conduit arteries, the increased load due to pulse
pressure also represents a strong determinant of wall thickness.
We investigated the effects of antihypertension treatment
on the elastic properties of the CCA. After 9 months of
antihypertension treatment with the perindopril- or the
HCTZ-plus-amiloride–based regimen, the CCA exhibited a
significant increase in cross-sectional compliance and distensi-
bility. Although improvement in large artery compliance with
ACE inhibitors has been largely reported in patients with
hypertension (22,33,49), the effects of diuretics are less consis-
tent (33,50). No change was observed at the site of the brachial
and common carotid and femoral arteries after treatment with
hydrochlorothiazide or in dapamide in controlled studies (50).
In a long-term controlled study, Kool et al. (33) observed that
a 6-month treatment with perindopril significantly increased
carotid artery distensibility and compliance, whereas HCTZ
plus amiloride did not. The reasons for the discrepancy
between the results of the study by Kool et al. (33) and those
of the present study are unclear, but three hypotheses can be
suggested. Although no significant difference in blood pressure
reduction was observed between both treatments in the study
by Kool et al. (33), blood pressure tended to be reduced to a
greater extent in the perindopril-treated group, a change that
may have contributed to the greater improvement in carotid
compliance in these patients. A second possibility is that the
pressure-independent effect of ACE inhibition on large arter-
ies had been offset in elderly patients by the prevailing role of
blood pressure reduction or by the lack of counterregulatory
mechanisms (activation of the renin-angiotensin and sympa-
thetic nervous systems) after treatment with diuretics in the
elderly. Third, diuretics, which are effective in the reduction of
pulse pressure and SBP in the elderly (18–20), very likely
improved carotid compliance through their blood pressure–
lowering effect. Thus, in the population of the present study
(i.e., elderly patients with systolic hypertension), antihyperten-
sion treatments improved CCA compliance mainly through a
pressure-dependent mechanism. In this context, the significant
relationship that we observed between the reversibility of
arterial hypertrophy and the reduction in the pulsatile (and not
steady) component of blood pressure is of major interest.
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The lack of reduction in radial and carotid artery diameters
along with the decrease in blood pressure during treatment
may be due to various mechanisms, including a direct vasodi-
lating effect of the antihypertensive agents and a chronic
remodeling process aimed at maintaining the circumferential
wall stress as unchanged (8).
Conclusions. These results indicate that in elderly patients
with hypertension both ACE inhibitor– and diuretic-based
treatments can reduce radial artery wall hypertrophy and
improve carotid artery compliance. They suggest that the
pressure-dependent increase in carotid distensibility and com-
pliance, which likely reflects the improvement in systemic
distensibility and compliance, may lead to a reduction in pulse
pressure and the subsequent reduction in radial artery wall
thickness/radius ratio.
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